Biotechnology - Biotechnology

Filter

Current filters:

Biotechnology

Popular Filters

1 to 25 of 2322 results

European Commission approves Gilead’s Zydelig for blood cancer

European Commission approves Gilead’s Zydelig for blood cancer

19-09-2014

The European Commission has granted marketing authorization for US biotech major Gilead Sciences’ Zydelig…

BiotechnologyEuropeGilead SciencesLymphomaMedicineOncologyRegulationZydelig

Orphan status for Navidea’s Lymphoseek in head and neck cancers

Orphan status for Navidea’s Lymphoseek in head and neck cancers

19-09-2014

US biotech company Navidea Biopharmaceuticals that its Lymphoseek (technetium Tc 99m tilmanocept) Injection…

BiotechnologyLymphoseekNavidea BiopharmaceuticalsOncologyRegulationUSA

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

19-09-2014

Nordic biotech firm Swedish Orphan Biovitrum has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF…

Biogen IdecBiotechnologyHematologyLicensingSobiSweden

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

18-09-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA has entered into a collaboration and license agreement…

BiotechnologyEMD SeronoLicensingMerck KGaAOncologyResearchUSA

Australian government announces funding available for Soliris

18-09-2014

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended to the Australian government that…

Alexion PharmaceuticalsAustraliaBiotechnologyFinancialPricingRare diseasesSoliris

EuropaBio calls for EMA action on labeling of biosimilars

18-09-2014

EuropaBio has published a statement giving the perspective of the health care biotechnology industry…

BiosimilarsBiotechnologyEuropeRegulation

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

Gilead’s simtuzumab fails in Ph II pancreatic cancer study

17-09-2014

US biotech major Gilead Sciences has announced disappointing results from a Phase II study evaluating…

BiotechnologyGilead SciencesOncologyResearchsimtuzumabUSA

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

Dimension Therapeutics appoints Annalisa Jenkins as chief executive

17-09-2014

Dimension Therapeutics, a US gene therapy company focused on rare diseases, has appointed Annalisa Jenkins…

BiotechnologyBoardroomDimension TheapeuticsDimension TherapeuticsUSA

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

17-09-2014

Privately-held San Diego, USA-based biotech firm Denovo Biopharma has acquired enzastaurin, a late-stage…

BiotechnologyDenovo BiopharmaEli LillyenzastaurinGlobalLicensingOncology

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

First therapy under UK’s early access scheme to be Northwest Biotherapeutics’ DCVax-L

17-09-2014

The UK’s Department of Health announced that DCVax-L, the dendritic cell-based vaccine from US company…

BiotechnologyDCVaxNorthwest BiotherapeuticsOncologyRegulationUK

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

FDA grants Breakthrough status for Eylea in diabetic retinopathy in patients with DME

16-09-2014

US biotech firm Regeneron Pharmaceuticals says that the US Food and Drug Administration has granted Eylea…

BayerBiotechnologyEyleaOphthalmicsRegeneron PharmaceuticalsRegulationUSA

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

Amgen updates on Prolia in postmenopausal osteoporosis

Amgen updates on Prolia in postmenopausal osteoporosis

16-09-2014

USA-based Amgen has released results from a new exploratory analysis of the open-label extension study…

AmgenAnti-Arthritics/RheumaticsBiotechnologyProliaResearchWomen's Health

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

Huya Bioscience to collaborate with Tianjin Institute on global development project from China

Huya Bioscience to collaborate with Tianjin Institute on global development project from China

15-09-2014

Huya Bioscience International, a global biopharma company specializing in biopharma opportunities originating…

BiotechnologyChinaHuya Bioscience InternationalResearchTianjin Institute of Pharmaceutical Research

Monoclonal antibodies set for a boom by 2019 due to favorable market conditions

Monoclonal antibodies set for a boom by 2019 due to favorable market conditions

15-09-2014

The monoclonal antibodies market for gastric and esophageal cancer is expected to double by 2019, according…

AntibodiesBiotechnologyEli LillyGlobalHerceptinnimotuzumabonartuzumabOncologypertuzumabramucirumabResearchRocheYM Biosciences

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

Cheaper alternative to licensed drug for treating eye disease has similar side-effects, says new Cochrane Review

15-09-2014

Health policies which favor using ranibizumab for treating eye disease in older people over safety concerns…

AvastinbevacizumabBiotechnologyEuropeLucentisNovartisOphthalmicsPricingRanibizumab InjectionRoche

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Merck Serono pulls plug on tecemotide in Stage III NSCLC

Merck Serono pulls plug on tecemotide in Stage III NSCLC

12-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, is to discontinue the clinical development…

BiotechnologyGermanyMerck SeronoOncologyResearch

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

1 to 25 of 2322 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top